Blastic plasmacytoid dendritic cell neoplasm following Waldenström macroglobulinemia

  title={Blastic plasmacytoid dendritic cell neoplasm following Waldenstr{\"o}m macroglobulinemia},
  author={Sarah Milley and Luc Thomas and Brigitte Balme and Stéphane Dalle},
  journal={Journal of the European Academy of Dermatology and Venereology},
  • S. Milley, L. Thomas, +1 author S. Dalle
  • Published 1 May 2016
  • Medicine
  • Journal of the European Academy of Dermatology and Venereology
References 1 Nofal A, Sanad M, Assaf M et al. Juvenile hyaline fibromatosis and infantile systemic hyalinosis: a unifying term and a proposed grading system. J Am Acad Dermatol 2009; 61: 695–700. 2 Hanks S, Adams S, Douglas J et al. Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003; 73: 791–800. 3 Tanaka K, Ebihara T, Kusubata M et al. Abnormal collagen deposition in fibromas from patient… Expand
2 Citations
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review
Age was shown to be an independent prognostic factor predictive of more favorable outcomes across measures including initial response to therapy, likelihood of relapse, and overall survival at follow-up, and allogeneic stem cell transplantation was shows to increase mean survival time. Expand
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.
The results highlight the heterogeneity of BPDCN, with a risk of a diagnostic trap, and various markers suggest an AS-DC origin, but not in all patients, and some of these abnormalities are related to the leukemogenesis process, such as the 9p deletion. Expand


TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm
Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab with a case series and comprehensive review of the literature. Expand
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
In conclusion, blastic plasmacytoid dendritic cell neoplasm with bone-marrow involvement is an aggressive subtype of high-risk acute leukemia and prospective clinical trials to identify the better therapeutic strategy are not enabled. Expand
Blastic Plasmacytoid Dendritic Cell Neoplasm Expressing the CD13 Myeloid Antigen
The present patient received 2 courses of combination chemotherapy consisting of cytarabine and etoposide, which resulted in complete remission, and myeloid antigen expression involving CD13 may not exclude a diagnosis of BPDCN. Expand
CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells.
Although questions remain, delineation of the CD4+/CD56+ hematodermic tumor and its improved recognition has already served as a catalyst toward better understanding of the multilineage potential of hematopoietic malignancies. Expand
Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia
This study validated pDCL‐specific markers for diagnosis by flow‐cytometry or quantitative reverse transcription polymerase chain reaction on bone marrow samples and proposed a diagnosis strategy, scoring first the CD4+ CD56+/− MPOneg cCD3neg cCD79aneg CD11cneg profile and then the CD123high,BDCA‐2 and BDCA‐4 expression. Expand
Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors.
It is shown that thrombopoietin (TPO) cooperates with FLT3-L, inducing CD34+ HPCs to undergo a 400-fold expansion in cell numbers and to generate more than 6 x 10 IPCs per 10(6) CD34-HPCs within 30 days in culture. Expand
Transcription Factor E2-2 Is an Essential and Specific Regulator of Plasmacytoid Dendritic Cell Development
It is reported that basic helix-loop-helix transcription factor E2-2/Tcf4 is preferentially expressed in murine and human PDCs and revealed a key function of E proteins in the innate immune system. Expand
Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.
The results demonstrate that the expression of CD33 on CD4(+)CD56(+) lineage-negative cells should not exclude the diagnosis of pDC leukemia and underline that pDC-specific markers should be used at diagnosis for CD4 (+)CD 56(+) malignancies. Expand
The ETS Transcription Factor Spi-B Is Required for Human Plasmacytoid Dendritic Cell Development
Results identify Spi-B as a key regulator of human pDC development as well as the related ETS factor PU.1, which inhibited in vitro development of CD34+ cells into pDCs. Expand
CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry
The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification, and CD304 was repeatedly expressed in patients with TEL‐AML1 gene rearrangement, which warrants further investigation on its potential relevance as a prognosis marker or therapeutic target. Expand